Advertisement

Index by author

February 01, 1995; Volume 272,Issue 2

A

  1. Adachi, H

    1. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;

  2. Adrien, J

    1. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;

  3. Aguilar, H

    1. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
      R Botla, J R Spivey, H Aguilar, S F Bronk and G J Gores
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 930-938;

  4. Albrightson, C R

    1. Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;

  5. Alling, D W

    1. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;

  6. Alvarez, I

    1. Some novel 5-hydroxytryptamine1A (5-HT1A) receptor agonists reduce gastric acid and pepsin secretion, reduce experimental gastric mucosal injury and enhance gastric mucus in rats.
      A J Farré, M Colombo, I Alvarez and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 832-837;

  7. Andersson, R G

    1. Pertussis toxin attenuates presynaptic inhibition of cholinergic but not nonadrenergic noncholinergic contraction in guinea pig airways.
      I G Johansson-Rydberg, N Grundström and R G Andersson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 786-790;

  8. Apparsundaram, S

    1. Role of prejunctional beta adrenoceptors in rat cardiac sympathetic neurotransmission.
      S Apparsundaram and D C Eikenburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 519-526;

  9. Atchison, W D

    1. The paralytic agent 2,4-dithiobiuret decreases open time of murine skeletal muscle acetylcholine receptor channels.
      J M Spitsbergen and W D Atchison
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 645-651;

  10. Awazu, S

    1. Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells.
      M Tomita, M Hayashi and S Awazu
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 739-743;

  11. Azorlosa, J L

    1. Marijuana smoking: effects of varying puff volume and breathhold duration.
      J L Azorlosa, M K Greenwald and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 560-569;

B

  1. Badger, A M

    1. Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;

  2. Banks, S M

    1. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;

  3. Barg, J

    1. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;

  4. Beauchamp, H T

    1. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
      H T Beauchamp, R S Chang, P K Siegl and R E Gibson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 612-618;

  5. Bédard, P J

    1. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;

  6. Bell, R L

    1. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;

  7. Bemis, K G

    1. In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
      G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;

  8. Berkhout, T A

    1. Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;

  9. Bigelow, G E

    1. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 628-638;

  10. Blanchet, P J

    1. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;

  11. Bloom, F E

    1. Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response.
      J Raber, G F Koob and F E Bloom
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 815-824;

  12. Bonkovsky, H L

    1. Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;

  13. Botla, R

    1. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
      R Botla, J R Spivey, H Aguilar, S F Bronk and G J Gores
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 930-938;

  14. Boulanger, C M

    1. Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.
      B Desta, M Nakashima, M Kirchengast, P M Vanhoutte and C M Boulanger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 885-891;

  15. Bouska, J B

    1. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;

  16. Bridal, T R

    1. Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes.
      F G de Lorenzi, T R Bridal and W Spinelli
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 714-723;

  17. Bronk, S F

    1. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
      R Botla, J R Spivey, H Aguilar, S F Bronk and G J Gores
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 930-938;

  18. Brooks, D W

    1. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;

  19. Brune, K A

    1. In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
      G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;

  20. Bugelski, P J

    1. Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;

  21. Butelman, E R

    1. Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.
      E R Butelman, G Winger, G Zernig and J H Woods
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 845-853;

  22. Butler, A M

    1. Identification of a reversible component in the in vitro inhibition of rat hepatic cytochrome P450 2B1 by parathion.
      M Murray and A M Butler
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 639-644;

C

  1. Cable, E E

    1. Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;

  2. Calon, F

    1. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;

  3. Campos, H A

    1. Interaction between noradrenergic and histamine-containing neurons in the rat vas deferens.
      H A Campos and J Domínguez
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 732-738;

  4. Carpéné, C

    1. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;

  5. Carter, D B

    1. [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
      G H Dillon, W B Im, J F Pregenzer, D B Carter and B J Hamilton
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 597-603;

  6. Carter, G W

    1. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;

  7. Chang, R S

    1. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
      H T Beauchamp, R S Chang, P K Siegl and R E Gibson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 612-618;

  8. Chastanet, M

    1. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;

  9. Chiba, S

    1. Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;
    2. Are negative chronotropic and inotropic responses to adenosine differentiated at the receptor or postreceptor levels in isolated dog hearts?
      T Oguchi, Y Furukawa, S Sawaki, M Kasama and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 838-844;

  10. Chikkala, D N

    1. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors.
      J E Piletz, D N Chikkala and P Ernsberger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 581-587;

  11. Childers, S R

    1. Behavioral and local cerebral metabolic effects of the novel tropane analog, 2 beta-propanoyl-3 beta-(4-tolyl)-tropane.
      L J Porrino, H M Davies and S R Childers
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 901-910;

  12. Collon, P

    1. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;

  13. Colombo, M

    1. Some novel 5-hydroxytryptamine1A (5-HT1A) receptor agonists reduce gastric acid and pepsin secretion, reduce experimental gastric mucosal injury and enhance gastric mucus in rats.
      A J Farré, M Colombo, I Alvarez and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 832-837;

  14. Cordi, A

    1. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;

  15. Cuello, A C

    1. Pharmacological characterization of nerve growth factor and/or monosialoganglioside GM1 effects on cholinergic markers in the adult lesioned brain.
      L Garofalo and A C Cuello
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 527-545;

D

  1. Danner, R L

    1. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;

  2. Dantzler, W H

    1. Kinetics of interactions of para-aminohippurate, probenecid, cysteine conjugates and N-acetyl cysteine conjugates with basolateral organic anion transporter in isolated rabbit proximal renal tubules.
      W H Dantzler, K K Evans and S H Wright
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 663-672;

  3. Davies, H M

    1. Behavioral and local cerebral metabolic effects of the novel tropane analog, 2 beta-propanoyl-3 beta-(4-tolyl)-tropane.
      L J Porrino, H M Davies and S R Childers
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 901-910;

  4. de Lorenzi, F G

    1. Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes.
      F G de Lorenzi, T R Bridal and W Spinelli
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 714-723;

  5. Desforges, B

    1. Effects of morphine on the pathogenesis of murine Friend retrovirus infection.
      M L Veyries, M Sinet, B Desforges and B Rouveix
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 498-504;

  6. Desta, B

    1. Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.
      B Desta, M Nakashima, M Kirchengast, P M Vanhoutte and C M Boulanger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 885-891;

  7. De Vry, J

    1. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;

  8. Diana, M

    1. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats.
      M Diana, M Pistis, A Muntoni and G Gessa
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 781-785;

  9. Dillon, G H

    1. [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
      G H Dillon, W B Im, J F Pregenzer, D B Carter and B J Hamilton
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 597-603;

  10. Di Paolo, T

    1. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;

  11. Domínguez, J

    1. Interaction between noradrenergic and histamine-containing neurons in the rat vas deferens.
      H A Campos and J Domínguez
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 732-738;

  12. Donohue, S

    1. Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;

  13. Drew, G M

    1. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

  14. Dubé, G P

    1. In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
      G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;

  15. Dumont, Y

    1. Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.
      Y Dumont, A Fournier, S St-Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 673-680;

  16. Dykstra, L A

    1. Mechanisms whereby macrophage-derived nitric oxide is involved in morphine-induced suppression of splenic lymphocyte proliferation.
      K Fecho, K A Maslonek, L A Dykstra and D T Lysle
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 477-483;

E

  1. Eikenburg, D C

    1. Role of prejunctional beta adrenoceptors in rat cardiac sympathetic neurotransmission.
      S Apparsundaram and D C Eikenburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 519-526;

  2. Elin, R J

    1. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;

  3. Ernsberger, P

    1. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors.
      J E Piletz, D N Chikkala and P Ernsberger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 581-587;

  4. Evans, K K

    1. Kinetics of interactions of para-aminohippurate, probenecid, cysteine conjugates and N-acetyl cysteine conjugates with basolateral organic anion transporter in isolated rabbit proximal renal tubules.
      W H Dantzler, K K Evans and S H Wright
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 663-672;

F

  1. Faiman, M D

    1. Characterization of diethyldithiocarbamate methyl ester sulfine as an intermediate in the bioactivation of disulfiram.
      A Madan and M D Faiman
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 775-780;

  2. Farfel, G M

    1. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX.
      G M Farfel and L S Seiden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 860-867;
    2. Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan.
      G M Farfel and L S Seiden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 868-875;

  3. Farré, A J

    1. Some novel 5-hydroxytryptamine1A (5-HT1A) receptor agonists reduce gastric acid and pepsin secretion, reduce experimental gastric mucosal injury and enhance gastric mucus in rats.
      A J Farré, M Colombo, I Alvarez and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 832-837;

  4. Fecho, K

    1. Mechanisms whereby macrophage-derived nitric oxide is involved in morphine-induced suppression of splenic lymphocyte proliferation.
      K Fecho, K A Maslonek, L A Dykstra and D T Lysle
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 477-483;

  5. Finkel, M S

    1. Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.
      M S Finkel, C V Oddis, O H Mayer, B G Hattler and R L Simmons
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 945-952;

  6. Fournier, A

    1. Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.
      Y Dumont, A Fournier, S St-Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 673-680;

  7. Fox, M

    1. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
      N C Trippodo, B C Panchal and M Fox
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 619-627;

  8. Fride, E

    1. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;

  9. Fujita, T

    1. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;

  10. Fukui, H

    1. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;

  11. Funae, Y

    1. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;

  12. Furukawa, Y

    1. Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;
    2. Are negative chronotropic and inotropic responses to adenosine differentiated at the receptor or postreceptor levels in isolated dog hearts?
      T Oguchi, Y Furukawa, S Sawaki, M Kasama and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 838-844;

G

  1. Garaulet, J V

    1. Cross-tolerance between kappa and mu opioid agonists in the guinea pig ileum myenteric plexus.
      J V Garaulet, M V Milanés and M L Laorden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 658-662;

  2. Garofalo, L

    1. Pharmacological characterization of nerve growth factor and/or monosialoganglioside GM1 effects on cholinergic markers in the adult lesioned brain.
      L Garofalo and A C Cuello
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 527-545;

  3. Gessa, G

    1. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats.
      M Diana, M Pistis, A Muntoni and G Gessa
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 781-785;

  4. Gibson, R E

    1. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
      H T Beauchamp, R S Chang, P K Siegl and R E Gibson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 612-618;

  5. Glaser, T

    1. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;

  6. Glavin, G B

    1. Some novel 5-hydroxytryptamine1A (5-HT1A) receptor agonists reduce gastric acid and pepsin secretion, reduce experimental gastric mucosal injury and enhance gastric mucus in rats.
      A J Farré, M Colombo, I Alvarez and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 832-837;

  7. Goldberg, S R

    1. Calcium channel blockers antagonize some of cocaine's cardiovascular effects, but fail to alter cocaine's behavioral effects.
      C W Schindler, S R Tella, J Prada and S R Goldberg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 791-798;

  8. Gores, G J

    1. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
      R Botla, J R Spivey, H Aguilar, S F Bronk and G J Gores
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 930-938;

  9. Grattagliano, I

    1. Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione.
      I Grattagliano, P Wieland, C Schranz and B H Lauterburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 484-488;

  10. Greenwald, M K

    1. Marijuana smoking: effects of varying puff volume and breathhold duration.
      J L Azorlosa, M K Greenwald and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 560-569;

  11. Griffiths, R R

    1. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.
      G K Mumford, C R Rush and R R Griffiths
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 570-580;

  12. Grundström, N

    1. Pertussis toxin attenuates presynaptic inhibition of cholinergic but not nonadrenergic noncholinergic contraction in guinea pig airways.
      I G Johansson-Rydberg, N Grundström and R G Andersson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 786-790;

  13. Guenthner, T M

    1. Metabolism of allylbenzene 2',3'-oxide and estragole 2',3'-oxide in the isolated perfused rat liver.
      G Luo and T M Guenthner
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 588-596;

H

  1. Hamilton, B J

    1. [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
      G H Dillon, W B Im, J F Pregenzer, D B Carter and B J Hamilton
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 597-603;

  2. Hamon, M

    1. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;

  3. Harris, R R

    1. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;

  4. Hattler, B G

    1. Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.
      M S Finkel, C V Oddis, O H Mayer, B G Hattler and R L Simmons
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 945-952;

  5. Hayashi, M

    1. Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells.
      M Tomita, M Hayashi and S Awazu
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 739-743;

  6. Heldman, E

    1. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;

  7. Hilditch, A

    1. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

  8. Hiroi, T

    1. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;

  9. Ho, A

    1. Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats: an in vivo microdialysis study.
      I M Maisonneuve, A Ho and M J Kreek
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 652-657;

  10. Hosseini, J M

    1. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;

  11. Hoyano, Y

    1. Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;

  12. Hudson, A

    1. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;

  13. Hunt, A A

    1. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

I

  1. Iga, T

    1. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
      M Ohtani, H Kotaki, Y Sawada and T Iga
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 505-510;

  2. Ihara, Y

    1. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;

  3. Im, W B

    1. [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
      G H Dillon, W B Im, J F Pregenzer, D B Carter and B J Hamilton
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 597-603;

  4. Imaoka, S

    1. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;

  5. Inoue, T

    1. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;

J

  1. Jackson, B

    1. Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;

  2. Jakubowski, J A

    1. In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
      G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;

  3. Johansson-Rydberg, I G

    1. Pertussis toxin attenuates presynaptic inhibition of cholinergic but not nonadrenergic noncholinergic contraction in guinea pig airways.
      I G Johansson-Rydberg, N Grundström and R G Andersson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 786-790;

  4. Jolas, T

    1. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;

  5. Judd, D B

    1. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

K

  1. Kagitani, Y

    1. Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;

  2. Kasama, M

    1. Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;
    2. Are negative chronotropic and inotropic responses to adenosine differentiated at the receptor or postreceptor levels in isolated dog hearts?
      T Oguchi, Y Furukawa, S Sawaki, M Kasama and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 838-844;

  3. Kawamura, T

    1. Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;

  4. Kawase, Y

    1. Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;

  5. Kerns, W D

    1. Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;

  6. Kirchengast, M

    1. Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.
      B Desta, M Nakashima, M Kirchengast, P M Vanhoutte and C M Boulanger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 885-891;

  7. Koev, C A

    1. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;

  8. Koob, G F

    1. Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response.
      J Raber, G F Koob and F E Bloom
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 815-824;

  9. Kotaki, H

    1. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
      M Ohtani, H Kotaki, Y Sawada and T Iga
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 505-510;

  10. Kreek, M J

    1. Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats: an in vivo microdialysis study.
      I M Maisonneuve, A Ho and M J Kreek
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 652-657;

  11. Kurtz, W L

    1. In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
      G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;

L

  1. Lafontan, M

    1. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;

  2. Lambrecht, R W

    1. Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;

  3. Lanni, C

    1. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;

  4. Laorden, M L

    1. Cross-tolerance between kappa and mu opioid agonists in the guinea pig ileum myenteric plexus.
      J V Garaulet, M V Milanés and M L Laorden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 658-662;

  5. Laporte, A M

    1. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;

  6. Lauterburg, B H

    1. Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione.
      I Grattagliano, P Wieland, C Schranz and B H Lauterburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 484-488;

  7. Levine, D M

    1. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;

  8. Levy, R

    1. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;

  9. Liebson, I A

    1. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 628-638;

  10. Linden, J

    1. Comparison of A4 and A2a binding sites in striatum and COS cells transfected with adenosine A2a receptors.
      D R Luthin and J Linden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 511-518;

  11. Little, H J

    1. Identification of distinct components, with different time courses, of the changes in response to convulsive stimuli during ethanol withdrawal.
      W P Watson and H J Little
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 876-884;

  12. Luo, G

    1. Metabolism of allylbenzene 2',3'-oxide and estragole 2',3'-oxide in the isolated perfused rat liver.
      G Luo and T M Guenthner
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 588-596;

  13. Luthin, D R

    1. Comparison of A4 and A2a binding sites in striatum and COS cells transfected with adenosine A2a receptors.
      D R Luthin and J Linden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 511-518;

  14. Lysle, D T

    1. Mechanisms whereby macrophage-derived nitric oxide is involved in morphine-induced suppression of splenic lymphocyte proliferation.
      K Fecho, K A Maslonek, L A Dykstra and D T Lysle
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 477-483;

M

  1. Madan, A

    1. Characterization of diethyldithiocarbamate methyl ester sulfine as an intermediate in the bioactivation of disulfiram.
      A Madan and M D Faiman
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 775-780;

  2. Maisonneuve, I M

    1. Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats: an in vivo microdialysis study.
      I M Maisonneuve, A Ho and M J Kreek
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 652-657;

  3. Malo, P E

    1. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;

  4. Martel, J C

    1. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;

  5. Maslonek, K A

    1. Mechanisms whereby macrophage-derived nitric oxide is involved in morphine-induced suppression of splenic lymphocyte proliferation.
      K Fecho, K A Maslonek, L A Dykstra and D T Lysle
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 477-483;

  6. Mayer, O H

    1. Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.
      M S Finkel, C V Oddis, O H Mayer, B G Hattler and R L Simmons
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 945-952;

  7. Mechoulam, R

    1. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;

  8. Middlemiss, D

    1. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

  9. Milanés, M V

    1. Cross-tolerance between kappa and mu opioid agonists in the guinea pig ileum myenteric plexus.
      J V Garaulet, M V Milanés and M L Laorden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 658-662;

  10. Min, K R

    1. Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;

  11. Moerschbaecher, J M

    1. Repeated acquisition of behavioral chains in squirrel monkeys: comparisons of a mu, kappa and delta opioid agonist.
      E D Pakarinen, J H Woods and J M Moerschbaecher
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 552-559;

  12. Mue, S

    1. Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;

  13. Mullikin-Kilpatrick, D

    1. Inhibition of dihydropyridine-sensitive Ca++ channels by ethanol in undifferentiated and nerve growth factor-treated PC12 cells: interaction with the inactivated state.
      D Mullikin-Kilpatrick and S N Treistman
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 489-497;

  14. Mumford, G K

    1. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.
      G K Mumford, C R Rush and R R Griffiths
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 570-580;

  15. Muntoni, A

    1. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats.
      M Diana, M Pistis, A Muntoni and G Gessa
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 781-785;

  16. Murray, M

    1. Identification of a reversible component in the in vitro inhibition of rat hepatic cytochrome P450 2B1 by parathion.
      M Murray and A M Butler
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 639-644;

N

  1. Nagai, H

    1. Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;

  2. Nakano, H

    1. Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;

  3. Nakashima, M

    1. Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.
      B Desta, M Nakashima, M Kirchengast, P M Vanhoutte and C M Boulanger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 885-891;

  4. Narita, Y

    1. Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;

  5. Natanson, C

    1. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;

  6. Nieves, A L

    1. Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
      D F Woodward, A L Nieves, C S Spada, L S Williams and R P Tuckett
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 758-765;

  7. Nocerini, M R

    1. A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography.
      M J Potchoiba, T G Tensfeldt, M R Nocerini and B M Silber
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 953-962;

  8. Nutt, D

    1. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;

O

  1. Oddis, C V

    1. Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.
      M S Finkel, C V Oddis, O H Mayer, B G Hattler and R L Simmons
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 945-952;

  2. Oguchi, T

    1. Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;
    2. Are negative chronotropic and inotropic responses to adenosine differentiated at the receptor or postreceptor levels in isolated dog hearts?
      T Oguchi, Y Furukawa, S Sawaki, M Kasama and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 838-844;

  3. Ohishi, N

    1. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;

  4. Ohnishi, A

    1. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;

  5. Ohtani, M

    1. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
      M Ohtani, H Kotaki, Y Sawada and T Iga
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 505-510;

  6. Ohuchi, K

    1. Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;

  7. Organ, A J

    1. Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;

  8. Orita, Y

    1. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;

  9. Orzi, F

    1. Effects of acute and delayed effects of prior chronic cocaine administration on regional rates of cerebral protein synthesis in rats.
      F Orzi, Y Sun, K Pettigrew, L Sokoloff and C B Smith
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 892-900;

  10. Otis, E R

    1. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;

P

  1. Pakarinen, E D

    1. Repeated acquisition of behavioral chains in squirrel monkeys: comparisons of a mu, kappa and delta opioid agonist.
      E D Pakarinen, J H Woods and J M Moerschbaecher
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 552-559;

  2. Panchal, B C

    1. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
      N C Trippodo, B C Panchal and M Fox
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 619-627;

  3. Parker, T S

    1. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;

  4. Pepe, J A

    1. Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;

  5. Perrault, G

    1. Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats.
      D J Sanger and G Perrault
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 708-713;

  6. Pettigrew, K

    1. Effects of acute and delayed effects of prior chronic cocaine administration on regional rates of cerebral protein synthesis in rats.
      F Orzi, Y Sun, K Pettigrew, L Sokoloff and C B Smith
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 892-900;

  7. Piercey, M F

    1. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;

  8. Piletz, J E

    1. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors.
      J E Piletz, D N Chikkala and P Ernsberger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 581-587;

  9. Pistis, M

    1. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats.
      M Diana, M Pistis, A Muntoni and G Gessa
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 781-785;

  10. Polley, J

    1. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

  11. Porrino, L J

    1. Behavioral and local cerebral metabolic effects of the novel tropane analog, 2 beta-propanoyl-3 beta-(4-tolyl)-tropane.
      L J Porrino, H M Davies and S R Childers
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 901-910;

  12. Potchoiba, M J

    1. A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography.
      M J Potchoiba, T G Tensfeldt, M R Nocerini and B M Silber
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 953-962;

  13. Prada, J

    1. Calcium channel blockers antagonize some of cocaine's cardiovascular effects, but fail to alter cocaine's behavioral effects.
      C W Schindler, S R Tella, J Prada and S R Goldberg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 791-798;

  14. Pregenzer, J F

    1. [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
      G H Dillon, W B Im, J F Pregenzer, D B Carter and B J Hamilton
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 597-603;

  15. Preston, K L

    1. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 628-638;

Q

  1. Quezado, Z M

    1. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;

  2. Quirion, R

    1. Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.
      Y Dumont, A Fournier, S St-Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 673-680;

R

  1. Raber, J

    1. Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response.
      J Raber, G F Koob and F E Bloom
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 815-824;

  2. Remaury, A

    1. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;

  3. Robertson, M J

    1. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

  4. Ross, B C

    1. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

  5. Rouveix, B

    1. Effects of morphine on the pathogenesis of murine Friend retrovirus infection.
      M L Veyries, M Sinet, B Desforges and B Rouveix
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 498-504;

  6. Rush, C R

    1. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.
      G K Mumford, C R Rush and R R Griffiths
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 570-580;

  7. Russo, S M

    1. Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;

S

  1. Saeki, T

    1. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;

  2. Saito, I

    1. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;

  3. Sanger, D J

    1. Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats.
      D J Sanger and G Perrault
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 708-713;

  4. Sawada, Y

    1. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
      M Ohtani, H Kotaki, Y Sawada and T Iga
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 505-510;

  5. Sawaki, S

    1. Are negative chronotropic and inotropic responses to adenosine differentiated at the receptor or postreceptor levels in isolated dog hearts?
      T Oguchi, Y Furukawa, S Sawaki, M Kasama and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 838-844;

  6. Saya, D

    1. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;

  7. Schindler, C W

    1. Calcium channel blockers antagonize some of cocaine's cardiovascular effects, but fail to alter cocaine's behavioral effects.
      C W Schindler, S R Tella, J Prada and S R Goldberg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 791-798;

  8. Schranz, C

    1. Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione.
      I Grattagliano, P Wieland, C Schranz and B H Lauterburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 484-488;

  9. Schreiber, R

    1. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;

  10. Seiden, L S

    1. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX.
      G M Farfel and L S Seiden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 860-867;
    2. Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan.
      G M Farfel and L S Seiden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 868-875;

  11. Shinyama, H

    1. Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;

  12. Siegl, P K

    1. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
      H T Beauchamp, R S Chang, P K Siegl and R E Gibson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 612-618;

  13. Silber, B M

    1. A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography.
      M J Potchoiba, T G Tensfeldt, M R Nocerini and B M Silber
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 953-962;

  14. Simmons, R L

    1. Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.
      M S Finkel, C V Oddis, O H Mayer, B G Hattler and R L Simmons
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 945-952;

  15. Sinet, M

    1. Effects of morphine on the pathogenesis of murine Friend retrovirus infection.
      M L Veyries, M Sinet, B Desforges and B Rouveix
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 498-504;

  16. Smith, C B

    1. Effects of acute and delayed effects of prior chronic cocaine administration on regional rates of cerebral protein synthesis in rats.
      F Orzi, Y Sun, K Pettigrew, L Sokoloff and C B Smith
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 892-900;

  17. Sokoloff, L

    1. Effects of acute and delayed effects of prior chronic cocaine administration on regional rates of cerebral protein synthesis in rats.
      F Orzi, Y Sun, K Pettigrew, L Sokoloff and C B Smith
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 892-900;

  18. Souda, S

    1. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;

  19. Spada, C S

    1. Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
      D F Woodward, A L Nieves, C S Spada, L S Williams and R P Tuckett
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 758-765;

  20. Spinelli, W

    1. Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes.
      F G de Lorenzi, T R Bridal and W Spinelli
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 714-723;

  21. Spitsbergen, J M

    1. The paralytic agent 2,4-dithiobiuret decreases open time of murine skeletal muscle acetylcholine receptor channels.
      J M Spitsbergen and W D Atchison
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 645-651;

  22. Spivey, J R

    1. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
      R Botla, J R Spivey, H Aguilar, S F Bronk and G J Gores
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 930-938;

  23. St-Pierre, S

    1. Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.
      Y Dumont, A Fournier, S St-Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 673-680;

  24. Stewart, A O

    1. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;

  25. Stitzer, M L

    1. Marijuana smoking: effects of varying puff volume and breathhold duration.
      J L Azorlosa, M K Greenwald and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 560-569;

  26. Strain, E C

    1. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 628-638;

  27. Sun, Y

    1. Effects of acute and delayed effects of prior chronic cocaine administration on regional rates of cerebral protein synthesis in rats.
      F Orzi, Y Sun, K Pettigrew, L Sokoloff and C B Smith
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 892-900;

T

  1. Takagi, N

    1. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;

  2. Takase, Y

    1. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;

  3. Tanabe, J

    1. Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;

  4. Tanaka, T

    1. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;

  5. Tella, S R

    1. Calcium channel blockers antagonize some of cocaine's cardiovascular effects, but fail to alter cocaine's behavioral effects.
      C W Schindler, S R Tella, J Prada and S R Goldberg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 791-798;

  6. Tensfeldt, T G

    1. A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography.
      M J Potchoiba, T G Tensfeldt, M R Nocerini and B M Silber
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 953-962;

  7. Tomita, M

    1. Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells.
      M Tomita, M Hayashi and S Awazu
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 739-743;

  8. Toyoki, T

    1. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;

  9. Travers, A

    1. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

  10. Treistman, S N

    1. Inhibition of dihydropyridine-sensitive Ca++ channels by ethanol in undifferentiated and nerve growth factor-treated PC12 cells: interaction with the inactivated state.
      D Mullikin-Kilpatrick and S N Treistman
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 489-497;

  11. Trippodo, N C

    1. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
      N C Trippodo, B C Panchal and M Fox
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 619-627;

  12. Tuckett, R P

    1. Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
      D F Woodward, A L Nieves, C S Spada, L S Williams and R P Tuckett
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 758-765;

U

  1. Uchida, T

    1. Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;

V

  1. Vanhoutte, P M

    1. Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.
      B Desta, M Nakashima, M Kirchengast, P M Vanhoutte and C M Boulanger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 885-891;

  2. Veyries, M L

    1. Effects of morphine on the pathogenesis of murine Friend retrovirus infection.
      M L Veyries, M Sinet, B Desforges and B Rouveix
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 498-504;

  3. Vogel, Z

    1. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;

W

  1. Walters, R R

    1. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;

  2. Watanabe, M

    1. Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;
    2. Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;

  3. Watson, W P

    1. Identification of distinct components, with different time courses, of the changes in response to convulsive stimuli during ethanol withdrawal.
      W P Watson and H J Little
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 876-884;

  4. Wieland, P

    1. Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione.
      I Grattagliano, P Wieland, C Schranz and B H Lauterburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 484-488;

  5. Williams, L S

    1. Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
      D F Woodward, A L Nieves, C S Spada, L S Williams and R P Tuckett
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 758-765;

  6. Winger, G

    1. Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.
      E R Butelman, G Winger, G Zernig and J H Woods
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 845-853;

  7. Woods, J H

    1. Repeated acquisition of behavioral chains in squirrel monkeys: comparisons of a mu, kappa and delta opioid agonist.
      E D Pakarinen, J H Woods and J M Moerschbaecher
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 552-559;
    2. Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.
      E R Butelman, G Winger, G Zernig and J H Woods
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 845-853;

  8. Woodward, D F

    1. Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
      D F Woodward, A L Nieves, C S Spada, L S Williams and R P Tuckett
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 758-765;

  9. Wright, S H

    1. Kinetics of interactions of para-aminohippurate, probenecid, cysteine conjugates and N-acetyl cysteine conjugates with basolateral organic anion transporter in isolated rabbit proximal renal tubules.
      W H Dantzler, K K Evans and S H Wright
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 663-672;

Y

  1. Yabusaki, Y

    1. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;

  2. Yamamura, Y

    1. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;

  3. Yoshitake, S

    1. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;

Z

  1. Zernig, G

    1. Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.
      E R Butelman, G Winger, G Zernig and J H Woods
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 845-853;
Back to top

In this issue

Advertisement